Source: MarketScreener

Sierra: Sierra Oncology : Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

(marketscreener.com) - Data presented at the 25th European Hematology Association Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib -- Long-term tolerability facilitates sustained dose intensity and prolonged clinical activity; longest ongoing treatment now extends to 10 years - VANCOUVER,...https://www.marketscreener.com/SIERRA-ONCOLOGY-INC-33296232/news/Sierra-Oncology-Reports-Favorable-Long-Term-Safety-and-Dose-Intensity-Data-for-Momelotinib-30760941/?utm_medium=RSS&utm_content=20200612

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Stephen Dilly's photo - President & CEO of Sierra Oncology, Inc.

President & CEO

Stephen Dilly

CEO Approval Rating

90/100

Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more